Dernière mise à jour :
18/04/2024
Equipes de recherche - Clinical Pharmacy Department, University Hospital Necker-Enfants Malades   Pdf  
France
Hôpital
Clinical Pharmacy Department, University Hospital Necker-Enfants Malades
Paris
Bibliographie   Bibliographie   (11)  
1
Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease.
Querin B, Schweitzer-Chaput A, Cisternino S, Auvity S, Fauqueur A-S, Negbane A, Hadchouel A, Schlatter J, Cotteret C. (salvatore.cisternino@aphp.fr)
Pharmaceutics - 2023 - ,15, 957.
2
Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D, Secrétan P-H, Cotteret , Jacques-Gustave E, Greco C, Bodemer C, Schlatter J, Cisternino S. (philippe-henri.secretan@u-psud.fr)
Molecules - 2022 - ; 27(3): 1070.
3
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease.
Hinterlang M, Sebti M, Cotteret C, Vidal F, Neven B, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
The Scientific World Journal - 2022 -
4
Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
El Mershati S, Thouvenin A , Secretan P-H, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
Pharm Dev Technol - 2021 -
5
Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags.
Vidal F, Cotteret C, Negbane A, Sebti M, Hinterlang M, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
EJHP - 2021 -
6
Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions.
Ancedy D, Sebti M, Postaire M, Vidal F, Cisternino S. ()
Am J Hosp Pharm - 2021 - ;78,9:825–831
7
Voriconazole topical cream formulation: evidence for stability and antifungal activity.
Bouchand C, Nguyen D, Secretan P-H, Vidal F, Guery R, Auvity S, Cohen J.F, Lanternier (joel.schlatter@aphp.fr)
Int J Antimicrob Agents - 2020 - ; 56: 106083.
8
Stability of warfarin sodium flavoured preservative-free oral liquid formulations.
Schlatter J, Cisternino S. (joel.schlatter@ aphp.fr)
EJHP - 2018 - ; 25, e2
9
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions.
Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Do Nascimento Afonso V. ()
Int J Pharm Compound - 2015 - ; 19, 1: 73-77.
10
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition.
Bourget P, Amin A, Vidal F, Pieyre M, Dosso E.O, Beauvais R, Loeuillet R. ()
Int J Pharm Compound - 2014 - ; 18, 5: 427-431.
11
How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?
Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus J.C, Jouani B.-L., Merlette C, Nov?-Josserand R, Pages J, Panzo R (philippe.bourget@nck.aphp.fr)
Antimicrob Agents Chemother - 2014 - ; 58 : 2849-2855.

Liste des molécules   Molécules étudiées   (11)  
Immunosuppresseur Solution buvable Azathioprine
Antibiotique Injectable Ceftazidime
Anticancéreux Forme dermique Erlotinib
Antiinflammatoire Solution buvable Hydrocortisone
Antiinflammatoire Solution buvable Hydroxychloroquine sulfate
Anesthésique général Solution buvable Ketamine hydrochloride
Divers Solution buvable L-Methionine
Anticancéreux Injectable Pemetrexed diarginine
Anticancéreux Solution buvable Ruxolitinib
Antifongique Forme dermique Voriconazole
Anticoagulant Solution buvable Warfarin sodium

  Mentions Légales